The story of Sildenafil presents a intricate picture for shareholders. While the initial release generated substantial gains, the expiration of its intellectual property protection opened the door to off-brand competitors, dramatically diminishing sales. This presents a particular challenge for firms banking on comparable blockbuster offerings, sug

The legacy of Viagra, and its developer copyright, presents a challenging case study for investors. At first a blockbuster drug, producing billions in revenue , its intellectual property lapse created a flood of knock-off medications, significantly diminishing its position . While certain pharmaceutical companies may try to capitalize on male sexua